Ampersand Capital Partners Closes $1.5B AMP-26 Fund as Healthcare Infrastructure Attracts Institutional Capital

Boston-based Ampersand Capital Partners, a healthcare-focused private equity firm, has closed AMP-26, its newest flagship healthcare and life sciences investment fund, at its $1.5B hard cap. The fund was oversubscribed, completed through a single close, and raised in less than 5 months.

AMP-26 includes commitments from institutional investors spanning pensions, endowments, foundations, insurance companies, family offices, and funds of funds. The close expands Ampersand's assets under management to more than $4B and marks the firm's 12th primary fund since 1992.

Founded in 1988 by Richard A. Charpie and led today by Managing Partner Herb H. Hooper, Ampersand Capital Partners focuses on healthcare and life sciences businesses across lab products, lab services, contract manufacturing, pharma services, and specialty products.

The significance extends beyond the headline number. AMP-26 offers another signal that institutional capital continues flowing toward the infrastructure supporting healthcare innovation, even as much of the broader market remains focused on artificial intelligence, software platforms, and breakthrough therapies.

---

What Happened

In May 2026, Ampersand Capital Partners announced the close of AMP-26 with $1.5B in limited partner commitments, reaching the fund's hard cap. According to the firm's official announcement, the fund was oversubscribed, completed through a single close, and reached capacity in less than 5 months. The investor base includes pensions, endowments, foundations, insurance companies, family offices, and funds of funds.

AMP-26 represents Ampersand's 12th primary fund since 1992 and increases firmwide assets under management beyond $4B. Founded by Richard A. Charpie and led by Herb H. Hooper, the firm has spent nearly four decades focused on healthcare and life sciences investing. While many investment firms have expanded into adjacent sectors over the years, Ampersand has maintained a concentrated strategy centered on healthcare infrastructure, scientific services, and operationally critical businesses.

Fundraising speed often reveals more than fundraising size. Capital tends to move quickly when investors already understand the manager, the strategy, and the opportunity. AMP-26 feels less like a strategic shift and more like institutional investors reinforcing a thesis they have trusted for years.

---

Why This Matters

Markets tend to celebrate outcomes. Breakthrough therapies, billion-dollar acquisitions, AI-powered diagnostics, and scientific discoveries generate headlines because they are easy to see and easy to understand. The infrastructure supporting those outcomes rarely receives the same attention despite being essential to the innovation economy.

That is where Ampersand has built its reputation. The firm's investment focus spans Lab Products, Lab Services, Contract Manufacturing, Pharma Services, and Specialty Products. These businesses may not dominate conference stages or social feeds, but they provide the infrastructure enabling researchers, manufacturers, pharmaceutical companies, and healthcare organizations to operate effectively.

When institutional investors commit $1.5B to a fund centered on those markets, they are expressing confidence in the durability of healthcare infrastructure. The signal is not simply about Ampersand Capital Partners. It reflects continued demand for the businesses that make healthcare innovation possible long before the innovation becomes visible to the public.

---

Market Context

Healthcare and life sciences occupy a unique position in today's investment environment. Artificial intelligence continues attracting enormous amounts of capital. Enterprise software remains a core investment category. Cybersecurity spending continues expanding as digital threats become more sophisticated. Healthcare innovation, however, operates under a different set of realities.

New therapies require development infrastructure. Pharmaceutical companies require manufacturing partners. Research organizations depend on specialized tools, services, testing capabilities, and operational support. Behind every scientific breakthrough sits a network of businesses responsible for turning research into scalable outcomes.

Those realities create long-term demand for specialized healthcare infrastructure providers and help explain why investors continue backing firms with deep sector expertise. Healthcare and life sciences remain highly regulated, scientifically complex, and operationally demanding markets where specialization often becomes a competitive advantage rather than a limitation.

---

Competitive Landscape

The healthcare investment ecosystem includes firms focused on biotechnology, medical devices, diagnostics, healthcare software, and pharmaceutical innovation. Ampersand occupies a distinct position within that landscape. Rather than concentrating exclusively on breakthrough products or therapies, the firm has historically focused on the tools and services supporting the broader healthcare ecosystem.

That distinction matters because infrastructure businesses often benefit regardless of which specific technologies or therapies ultimately succeed. The strategy resembles investing in the systems that enable innovation rather than attempting to predict which innovation will emerge as the winner.

As healthcare ecosystems become increasingly interconnected, infrastructure-focused investment strategies gain exposure to multiple growth drivers simultaneously. Research, manufacturing, testing, and service delivery all depend on businesses operating behind the scenes. The AMP-26 fund close suggests institutional investors continue finding value in that approach.

---

What This Signals

The broader signal extends beyond Ampersand Capital Partners. Institutional investors have become more selective, placing greater emphasis on demonstrated expertise, sector knowledge, and repeatable investment strategies.

Against that backdrop, raising $1.5B at a hard cap carries significance. It reflects confidence not only in healthcare and life sciences but also in specialized investment managers capable of navigating those sectors. The market increasingly appears willing to reward specialization, particularly when it is supported by a long operating history and a clearly defined investment thesis.

That pattern extends across multiple areas of the technology ecosystem. Healthcare, cybersecurity, enterprise software, and infrastructure investing all exhibit similar dynamics. Capital continues flowing toward firms that understand their markets deeply rather than chasing every new narrative cycle.

---

The Bigger Industry Shift

One of the defining themes across modern technology and healthcare markets is a renewed appreciation for infrastructure. Artificial intelligence depends on compute infrastructure. Cybersecurity depends on security infrastructure. Healthcare innovation depends on scientific and operational infrastructure. Different sectors, same underlying pattern.

Founders often receive the attention. Products often receive the headlines. Entire industries, however, depend on businesses providing critical capabilities behind the scenes. Those companies rarely generate the same excitement as the technologies they support, but they frequently become indispensable components of larger ecosystems.

Ampersand's latest fundraise reinforces that reality. While public attention remains focused on breakthrough technologies, institutional capital continues flowing toward businesses that help entire industries operate more effectively. The systems behind innovation may not attract the spotlight, but they often become some of the most durable sources of value creation.

---